[1]王丽丽,王 佳,郝晓静.血清涎液化糖链抗原-6、分泌性磷蛋白1与肺炎支原体肺炎患儿病情程度相关性及联合预测预后的价值[J].陕西医学杂志,2025,54(3):333-337.[doi:DOI:10.3969/j.issn.1000-7377.2025.03.009]
　WANG Lili,WANG Jia,HAO Xiaojing.Correlation between serum KL-6,SPP1 levels with disease severity in MPP children and value of combination in predicting prognosis[J].,2025,54(3):333-337.[doi:DOI:10.3969/j.issn.1000-7377.2025.03.009]
点击复制

血清涎液化糖链抗原-6、分泌性磷蛋白1与肺炎支原体肺炎患儿病情程度相关性及联合预测预后的价值
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
54
期数:
2025年3期
页码:
333-337
栏目:
临床研究
出版日期:
2025-03-05

文章信息/Info

Title:
Correlation between serum KL-6,SPP1 levels with disease severity in MPP children and value of combination in predicting prognosis
作者:
王丽丽; 王 佳; 郝晓静
(河北省人民医院儿科,河北 石家庄 050051)
Author(s):
WANG Lili; WANG Jia; HAO Xiaojing
(Department of Pediatrics,Hebei General Hospital,Shijiazhuang 050051,China)
关键词:
肺炎支原体肺炎;  涎液化糖链抗原-6;  分泌性磷蛋白1;  病情程度;  预后;  预测
Keywords:
Mycoplasma pneumoniae pneumonia;  Krebsvon den lungen-6;  Secretory phosphoprotein 1;  Severity of disease;  Prognosis;  Prediction
分类号:
R 725.6
DOI:
DOI:10.3969/j.issn.1000-7377.2025.03.009
文献标志码:
A
摘要:
目的:探究血清涎液化糖链抗原-6(KL-6)、分泌性磷蛋白1(SPP1)与肺炎支原体肺炎(MPP)患儿病情程度的相关性及联合预测预后的价值。方法:选取MPP患儿190例,根据病情程度分为轻症组(99例)和重症组(91例)。另选体检健康儿童95例为对照组。比较三组一般资料及血清KL-6、SPP1水平,分析MPP患儿入院时血清KL-6、SPP1水平及病情程度间的相关性。根据MPP患儿28 d预后情况分为预后良好组(129例)和预后不良组(61例),比较两组临床资料及生化指标,分析MPP患儿预后的影响因素及血清KL-6、SPP1对MPP患儿预后不良的预测价值。结果:重症组入院时血清KL-6、SPP1水平高于轻症组和对照组,且轻症组高于对照组(均P<0.05)。MPP患儿入院时血清KL-6、SPP1水平与病情程度呈正相关,且血清KL-6与SPP1呈正相关(均P<0.05)。患病至治疗时间、入院时病情程度、肺炎严重指数(PSI)评分及血清KL-6、SPP1水平为MPP患儿预后的危险因素,第1秒用力呼气肺活量(FEV1)/用力肺活量(FVC)是保护因素(均P<0.05)。入院时血清KL-6、SPP1单独预测MPP患儿预后不良的曲线下面积(AUC)分别为0.717、0.708; 常规预测模型(患病至治疗时间、入院时病情程度、FEV1/FVC、PSI评分联合)预测MPP患儿预后不良的AUC为0.845,新预测模型(常规预测模型联合入院时血清KL-6、SPP1)预测MPP患儿预后不良的AUC为0.912,新预测模型的AUC明显大于常规预测模型的AUC(P<0.05)。结论:入院时血清KL-6、SPP1水平与MPP患儿病情程度呈正相关,且在预测患儿预后不良方面具有一定价值,与预后不良的常规影响因素联合能为临床预测预后不良高危患儿提供可靠临床依据。
Abstract:
Objective:To explore the correlation between serum krebsvon den lungen-6(KL-6),secretory phosphoprotein 1(SPP1)with disease severity in mycoplasmal pneumonia pneumonia(MPP)children and the value of combination in predicting prognosis.Methods:A total of 190 children with MPP were enrolled.According to the severity of the disease,they were divided into mild group with 99 children and severe group with 91 children.Another 95 healthy children were selected as the control group.The general data and serum KL-6 and SPP1 levels of the three groups were compared,and the correlation between the serum KL-6,SPP1 levels and the degree of disease on admission in children with MPP was analyzed.According to the 28-day prognosis of children with MPP,they were divided into good prognosis group(129 cases)and poor prognosis group(61 cases),and the clinical data and biochemical indicators of the two groups were compared,and the influencing factors of the prognosis of children with MPP and the predictive value of serum KL-6 and SPP1 for poor prognosis of children with MPP were analyzed.Results:The severe group had significantly higher serum levels of KL-6 and SPP1 than the mild group and the control group at admission,and the mild group had significantly higher serum levels of KL-6 and SPP1 than the control group(all P<0.05).In children with MPP,the serum levels of KL-6 and SPP1 at admission were positively correlated with the severity of the disease,and the serum levels of KL-6 and SPP1 were positively correlated(all P<0.05).The time from illness to treatment,disease severity at admission,PSI score,and the levels of serum KL-6 and SPP1 were risk factors for the prognosis of children with MPP,while FEV1/FVC was protective factor(all P<0.05).The AUC of serum KL-6 and SPP1 on admission alone to predict poor prognosis in children with MPP was 0.717 and 0.708,respectively.The AUC of the conventional prediction model(the combination of time from illness to treatment,disease severity at admission,FEV1/FVC,and PSI score)in predicting the poor prognosis of children with MPP was 0.845,and the AUC of the new prediction model(the combination of the conventional prediction model and serum KL-6 and SPP1 at admission)in predicting the poor prognosis of children with MPP was 0.912.The AUC of the new prediction model was significantly higher than that of the conventional prediction model(P<0.05).Conclusion:The serum levels of KL-6 and SPP1 at admission are positively correlated with the severity of disease in children with MPP and have certain value in predicting poor prognosis.In combination with the conventional influencing factors of poor prognosis,the serum levels of KL-6 and SPP1 can provide a reliable clinical basis for clinical prediction of poor prognosis in children with a high risk of poor prognosis.

参考文献/References:

[1] SONG Z,JIA G Y,LUO G Z,et al.Global research trends of Mycoplasma pneumoniae pneumonia in children:A bibliometric analysis[J].Front Pediatr,2023,11(1):1306234.
[2] LI S,ZHOU Y,YAN Y J,et al.Structure-based virtual screening,ADMET properties prediction and molecular dynamics studies reveal potential inhibitors of mycoplasma pneumoniae HPrK/P[J].Life(Basel),2024,14(6):657.
[3] 张燕.中性粒细胞淋巴细胞比值、血小板淋巴细胞比值在肺炎支原体感染患儿中的水平变化及临床意义[J].陕西医学杂志,2021,50(8):973-976.
[4] YAN C,XUE G H,ZHAO H Q,et al.Current status of mycoplasma pneumoniae infection in China[J].World J Pediatr,2024,20(1):1-4.
[5] XIE X Y,ZHOU R Y,DING S A,et al.Emerging trends and concerns in mycoplasma pneumoniae pneumonia among Chinese pediatric population[J].Pediatr Res,2024,95(6):1388-1390.
[6] 刘凯,付红敏,陆权.儿童肺炎支原体肺炎的流行病学新进展[J].中华儿科杂志,2024,62(7):696-699.
[7] GAO Y,DU T M,YANG L B,et al.Research progress of KL-6 in respiratory system diseases[J].Crit Rev Clin Lab Sci,2024,61(7):599-615.
[8] SÁNCHEZ-DÍEZ S,MUNOZ X,OJANGUREN I,et al.YKL-40 and KL-6 Levels in serum and sputum of patients diagnosed with hypersensitivity pneumonitis[J].J Allergy Clin Immunol Pract,2022,10(9):2414-2423.
[9] 李芳,金晓莉,宋义琴.血清KL-6对儿童难治性肺炎支原体肺炎的预测价值[J].中国病案,2023,24(1):102-105.
[10] KUMAR A,ELKO E,BRUNO S R,et al.Inhibition of PDIA3 in club cells attenuates osteopontin production and lung fibrosis[J].Thorax,2022,77(7):669-678.
[11] 中华人民共和国国家健康委员会,国家中医药局.儿童社区获得性肺炎诊疗规范(2019年版)[J].中华临床感染病杂志,2019,12(1):6-13.
[12] 国家卫生计生委合理用药专家委员会儿童用药专业组.中国儿童肺炎支原体感染实验室诊断规范和临床实践专家共识(2019年)[J].中华儿科杂志,2020,58(5):366-373.
[13] ZHANG H F,LI L Q,GE Y L,et al.Serum prealbumin improves the sensitivity of pneumonia severity index in predicting 30-day mortality of CAP patients[J].Clin Lab,2020,66(5):811-818.
[14] 欧芬,杨涛毅,李红霞,等.支原体肺炎患儿血清白细胞介素-17、核因子-κB水平检测及其与疾病严重程度关系研究[J].陕西医学杂志,2024,53(9):1245-1248.
[15] HAN Q,JIANG T T,WANG T Y,et al.Clinical value of monitoring cytokine levels for assessing the severity of mycoplasma pneumoniae pneumonia in children[J].Am J Transl Res,2024,16(8):3964-3977.
[16] WANG L P,HU Z H,JIANG J S,et al.Serum inflammatory markers in children with mycoplasma pneumoniae pneumonia and their predictive value for mycoplasma severity[J].World J Clin Cases,2024,12(22):4940-4946.
[17] 朱雪华,秦亦如,农骐郢,等.血清涎液化糖链抗原6对肺部疾病预警作用研究进展[J].中国职业医学,2023,50(1):104-109.
[18] CAMBIER M,HENKET M,FRIX A N,et al.Increased KL-6 levels in moderate to severe COVID-19 infection[J].PLoS One,2022,17(11):e0273107.
[19] 于雪,孟繁,蔡天池,等.肺炎支原体肺炎患儿血清miR-126-5p、SPP1表达水平与病情严重程度的相关性分析[J].临床和实验医学杂志,2023,22(7):730-733.
[20] 陈团营,王曼玉,吴文先.血清CCSP、CysLTs、KL-6水平对肺炎支原体肺炎患儿病情监测作用及其分析[J].实验与检验医学,2022,40(5):576-580.
[21] 梁文婷,霍开明,古裕鸟,等.肺炎支原体肺炎患儿血清MICA、OPN水平及其与反复呼吸道感染的相关性研究[J].检验医学与临床,2024,21(13):1870-1874.
[22] 解婷婷,卢芳,梁峰,等.匹多莫德联合氨溴特罗对支原体肺炎患儿血清KL-6、GM-CSF、炎症因子水平及免疫功能的干预作用[J].检验医学与临床,2022,19(8):1040-1044.
[23] 吕月华,赵丽,李婷.重症肺炎患儿临床特征及影响患儿预后的危险因素分析[J].实用预防医学,2024,31(3):314-318.
[24] 张庆,柴航,李晓慧,等.重症肺炎支原体肺炎患儿外周血miR-199a-3p表达水平及其对预后不良的预测价值[J].检验医学与临床,2023,20(11):1527-1531.
[25] 朱柏林,梁丽婷,李秀琴,等.肺炎支原体肺炎患儿血清HGF G-CSF表达及其预后相关性研究[J].中国妇幼保健,2023,38(2):262-265.

相似文献/References:

[1]杨明珠,韩改琳,倪 莉.布地奈德联合阿奇霉素序贯疗法对肺炎支原体肺炎患儿血清TNFα、CRP、IL5及VEGF的影响研究[J].陕西医学杂志,2019,(3):383.
[2]张洁如,王浩杰,许梅杰,等.涎液化糖链抗原-6、C-反应蛋白/白蛋白比值联合改良临床-影像-病理诊断评分在间质性肺疾病严重程度和预后评估中的应用[J].陕西医学杂志,2025,54(1):101.[doi:DOI:10.3969/j.issn.1000-7377.2025.01.020]

备注/Memo

备注/Memo:
[基金项目]河北省医学科学研究课题(20190370)
更新日期/Last Update: 2025-03-05